Imagen de Portada

Power and Sample Size Calculations for Bayes Factors in two-arm clinical Phase II Trials with binary Endpoints

Fuente: arXiv

Guardado en:

Detalles Bibliográficos
Autor principal:	Kelter, Riko
Formato:	Preprint
Publicado:	2026
Materias:	Methodology Applications
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Optimal sequential two-stage Bayes Factor Design for two-arm clinical Phase II Trials with binary Endpoints
por: Kelter, Riko
Publicado: (2026)

Bayesian Power and Sample Size Calculations for Bayes Factors in the Binomial Setting
por: Kelter, Riko, et al.
Publicado: (2025)

The Bayesian optimal two-stage design for clinical phase II trials based on Bayes factors
por: Kelter, Riko, et al.
Publicado: (2025)

Robust Power and Sample Size Calculations in Quasi-likelihood Models: Methods and Practice
por: Yuan, Shijie, et al.
Publicado: (2026)

Designing Efficient Hybrid and Single-Arm Trials: External Control Borrowing and Sample Size Calculation
por: Gao, Yujing, et al.
Publicado: (2025)

Unified and Simple Sample Size Calculations for Individual or Cluster Randomized Trials with Skewed or Ordinal Outcomes
por: Tu, Shengxin, et al.
Publicado: (2025)

BayesPPDSurv: An R Package for Bayesian Sample Size Determination Using the Power and Normalized Power Prior for Time-To-Event Data
por: Shen, Yueqi, et al.
Publicado: (2024)

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials
por: Maity, Arnab Kumar, et al.
Publicado: (2024)

Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
por: Long, James P., et al.
Publicado: (2025)

A Utility Score Framework for Dose Optimization Studies with Binary Efficacy-Safety Endpoints: Sample Size Determination and Bias Characterization
por: Gu, Xuemin, et al.
Publicado: (2026)

Sample Size Calculations for the Development of Risk Prediction Models that Account for Performance Variability
por: Pavlou, Menelaos, et al.
Publicado: (2025)

Toward Valid Generative Clinical Trial Data with Survival Endpoints
por: Chassat, Perrine, et al.
Publicado: (2025)

Study Duration Prediction for Clinical Trials with Time-to-Event Endpoints Using Mixture Distributions Accounting for Heterogeneous Population
por: Zhang, Hong, et al.
Publicado: (2023)

Sample Size Calculations for Developing Clinical Prediction Models: Overview and pmsims R package
por: Shamsutdinova, Diana, et al.
Publicado: (2026)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
por: Komaki, Moka, et al.
Publicado: (2025)

A non-parametric U-statistic testing approach for multi-arm clinical trials with multivariate longitudinal data
por: Ghosh, Dhrubajyoti, et al.
Publicado: (2024)

BMW: Bayesian Model-Assisted Adaptive Phase II Clinical Trial Design for Win Ratio Statistic
por: Zhu, Di, et al.
Publicado: (2026)

Comparison of Simulation-Guided Design to Closed-Form Power Calculations in Planning a Cluster Randomized Trial with Covariate-Constrained Randomization: A Case Study in Rural Chad
por: Park, Jay JH, et al.
Publicado: (2025)

Evaluation of Surrogate Endpoints Based on Meta-Analysis with Surrogate Indices
por: Stijven, Florian, et al.
Publicado: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
por: Hall, Andrew, et al.
Publicado: (2025)

Sample Size Selection under an Infill Asymptotic Domain
por: Natoli, Cory W., et al.
Publicado: (2024)

Covariate Ordered Systematic Sampling as an Improvement to Randomized Controlled Trials
por: Jobson, Deddy, et al.
Publicado: (2024)

Behavioral Carry-Over Effect and Power Consideration in Crossover Trials
por: Shi, Danni, et al.
Publicado: (2023)

Eliciting prior information from clinical trials via calibrated Bayes factor
por: Demartino, Roberto Macrì, et al.
Publicado: (2024)

Sample Design and Cross-sectional Weights for the Brazilian PCSVDF-Mulher Study: Integrating a Refreshment Sample with an Ongoing Longitudinal Wave to Calculate IPV Prevalence
por: Carvalho, José Raimundo, et al.
Publicado: (2023)

Optimal and Efficient Sample Size Re-estimation: A Dynamic Cost Framework
por: Jin, Rui, et al.
Publicado: (2025)

Bayesian Functional Analysis for Untargeted Metabolomics Data with Matching Uncertainty and Small Sample Sizes
por: Ma, Guoxuan, et al.
Publicado: (2023)

Tutorial for Surrogate Endpoint Validation Using Joint modeling and Mediation Analysis
por: Coent, Quentin Le, et al.
Publicado: (2025)

Closed-Form Power and Sample Size Calculations for Bayes Factors
por: Pawel, Samuel, et al.
Publicado: (2024)

Evaluating the impact of outcome delay on the efficiency of two-arm group-sequential trials
por: Mukherjee, Aritra, et al.
Publicado: (2023)

Multi-Dimensional Composite Endpoint Analysis via the Choquet Integral: Block Recurrent Encoding and Comparative Advantage Mapping
por: Tanboga, Ibrahim Halil
Publicado: (2026)

BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
por: Chen, Yuxuan, et al.
Publicado: (2026)

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
por: Lee, Kyong Ju, et al.
Publicado: (2025)

The FORSS Framework for Sample Size and Power Calculations With Win Statistics for Hierarchical Endpoints
por: Zhang, Baoshan, et al.
Publicado: (2026)

A multi-arm multi-stage design for trials with all pairwise testing
por: Greenstreet, Peter, et al.
Publicado: (2025)

Increasing power and robustness in screening trials by testing stored specimens in the control arm
por: Katki, Hormuzd A., et al.
Publicado: (2024)

MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials
por: Lyu, Jiaying, et al.
Publicado: (2020)

Cumulative Logit Ordinal Regression with Proportional Odds under Nonignorable Missing Response -- Application to Phase III Trial
por: Maity, Arnab Kumar, et al.
Publicado: (2025)

TAD-SIE: Sample Size Estimation for Clinical Randomized Controlled Trials using a Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator
por: Lala, Sayeri, et al.
Publicado: (2024)

Bayes Factor of Zero Inflated Models under Jeffereys Prior
por: Pramanik, Paramahansa, et al.
Publicado: (2024)